Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy
ACS Chemical Neuroscience · 2024
DOI: 10.1021/acschemneuro.3c00653 ↗At a glance
Journal article in ACS Chemical Neuroscience, 2024. Written by Akash Verma and 9 co-authors. Institution: Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology-Banaras Hindu University, Varanasi 221005, India. Major MEDLINE topics: Alzheimer Disease, Neuroblastoma. Cited 22 times so far (Crossref); 87 references.
Topics: Demenz
Abstract (original language)
An efficient and promising method of treating complex neurodegenerative diseases like Alzheimer's disease (AD) is the multitarget-directed approach. Here in this work, a series of quinazoline derivatives (AV-1 to AV-21) were rationally designed, synthesized, and biologically evaluated as multitargeted directed ligands against human cholinesterase (hChE) and human β-secretase (hBACE-1) that exhibit moderate to good inhibitory effects. Compounds AV-1, AV-2, and AV-3 from the series demonstrated balanced and significant inhibition against these targets. These compounds also displayed excellent blood-brain barrier permeability via the PAMPA-BBB assay. Compound AV-2 significantly displaced propidium iodide (PI) from the acetylcholinesterase-peripheral anionic site (AChE-PAS) and was found to be non-neurotoxic at the maximum tested concentration (80 μM) against differentiated SH-SY5Y cell lines. Compound AV-2 also prevented AChE- and self-induced Aβ aggregation in the thioflavin T assay. Additionally, compound AV-2 significantly ameliorated scopolamine and Aβ-induced cognitive impairments in the in vivo behavioral Y-maze and Morris water maze studies, respectively. The ex vivo and biochemical analysis further revealed good hippocampal AChE inhibition and the antioxidant potential of the compound AV-2. Western blot and immunohistochemical (IHC) analysis of hippocampal brain revealed reduced Aβ, BACE-1, APP/Aβ, and Tau molecular protein expressions levels. The pharmacokinetic analysis of compound AV-2 demonstrated significant oral absorption with good bioavailability. The in silico molecular modeling studies of lead compound AV-2 moreover demonstrated a reasonable binding profile with AChE and BACE-1 enzymes and stable ligand-protein complexes throughout the 100 ns run. Compound AV-2 can be regarded as the lead candidate and could be explored more for AD therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology-Banaras Hindu University, Varanasi 221005, India.
- Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi 221005, India.
ORCID profiles: Sushant Kumar Shrivastava
Cite
APA
Verma, A., Waiker, D. K., Singh, N., Roy, A., Singh, N., Saraf, P., Bhardwaj, B., Krishnamurthy, S., Trigun, S. K., & Shrivastava, S. K. (2024). Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.3c00653
Vancouver
Verma A, Waiker DK, Singh N, Roy A, Singh N, Saraf P, et al. Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy. ACS Chemical Neuroscience. 2024. doi:10.1021/acschemneuro.3c00653
BibTeX
@article{Verma2024,
author = {Verma, Akash and Waiker, Digambar Kumar and Singh, Neha and Roy, Anima and Singh, Namrata and Saraf, Poorvi and Bhardwaj, Bhagwati and Krishnamurthy, Sairam and Trigun, Surendra Kumar and Shrivastava, Sushant Kumar},
title = {Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer’s Disease Therapy},
journal = {ACS Chemical Neuroscience},
year = {2024},
doi = {10.1021/acschemneuro.3c00653}
}
EUVIMED